{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+and+Selected+Solid+Tumors&page=4", "query": { "condition": "Advanced and Selected Solid Tumors", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 182, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+and+Selected+Solid+Tumors&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+and+Selected+Solid+Tumors&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T05:55:27.230Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07807241", "title": "A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced and/or Metastatic Solid Tumors Known to Express B7-H3" ], "interventions": [ { "name": "MX006", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myricx Pharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-07-20", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 4, "location_summary": "Sarasota, Florida • Houston, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807241" }, { "nct_id": "NCT06400472", "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Endometrial Neoplasms", "Uterine Cervical Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Pancreatic Neoplasm", "Colorectal Neoplasms" ], "interventions": [ { "name": "Sofe-M", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 575, "start_date": "2024-05-20", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06400472" }, { "nct_id": "NCT07166601", "title": "M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "M0324", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2025-10-10", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 3, "location_summary": "New Haven, Connecticut • New York, New York • San Antonio, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07166601" }, { "nct_id": "NCT05585034", "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Melanoma Excluding Uveal Melanoma", "Non-small Cell Lung Cancer, Squamous or Non-squamous", "Urothelial Carcinoma", "Renal Cell Carcinoma, Clear Cell", "Castration-resistant Prostate Cancer", "Ovarian Cancer, Epithelial", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "XmAb®808", "type": "BIOLOGICAL" }, { "name": "Keytruda® (pembrolizumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-12-14", "completion_date": "2025-05-20", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585034" }, { "nct_id": "NCT02922764", "title": "A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Endometrial Cancer Recurrent", "Lung Cancer Recurrent", "Lung Cancer", "Non-small Cell Lung Cancer Metastatic", "Non-small Cell Carcinoma" ], "interventions": [ { "name": "RGX-104", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inspirna, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2016-11-01", "completion_date": "2025-01-22", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 21, "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02922764" }, { "nct_id": "NCT02221960", "title": "A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent or Metastatic Solid Tumors" ], "interventions": [ { "name": "MEDI6383", "type": "BIOLOGICAL" }, { "name": "MEDI6383 and MEDI4736", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 39, "start_date": "2014-09-15", "completion_date": "2017-07-03", "has_results": false, "last_update_posted_date": "2019-03-13", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 7, "location_summary": "La Jolla, California • New Haven, Connecticut • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02221960" }, { "nct_id": "NCT05848739", "title": "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colon Cancer", "Metastatic Colon Cancer" ], "interventions": [ { "name": "ST316", "type": "DRUG" }, { "name": "FOLFIRI regimen & bevacizumab", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" }, { "name": "Lonsurf & bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sapience Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-06-05", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05848739" }, { "nct_id": "NCT05001347", "title": "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Head and Neck Cancer", "Non Small Cell Lung Cancer", "Gastrointestinal Cancer", "Triple Negative Breast Cancer", "Ovarian Carcinoma" ], "interventions": [ { "name": "TJ004309", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-11-02", "completion_date": "2023-02-08", "has_results": true, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 15, "location_summary": "Tucson, Arizona • Whittier, California • Newark, Delaware + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Whittier", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001347" }, { "nct_id": "NCT05098132", "title": "Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Untreated Advanced NSCLC", "1st Line NSCLC" ], "interventions": [ { "name": "STK-012", "type": "DRUG" }, { "name": "pembrolizumab KEYTRUDA®", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synthekine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2022-01-25", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 33, "location_summary": "Tucson, Arizona • Beverly Hills, California • Fullerton, California + 26 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098132" }, { "nct_id": "NCT03811652", "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer Squamous (NSCLC-Sq)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Small Cell Lung Cancer (SCLC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Colorectal Cancer (CRC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "MEDI7247", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 8, "start_date": "2018-12-20", "completion_date": "2019-12-10", "has_results": false, "last_update_posted_date": "2019-12-30", "last_synced_at": "2026-10-09T05:55:27.230Z", "location_count": 2, "location_summary": "Huntersville, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03811652" } ] }